FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants.”
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the Alpha, Beta, Delta and Gamma VOCs. The results showed IC50 binding affinity of <5 for Tollovid and <1 for Tollovir for each of the different SARS-CoV-2 strains. The experiments were completed at Tel Aviv University in Israel.
Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.
For more information, please visit: Todos Medical Ltd.
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.